Fatigue News and Research

RSS

Skin-to-skin contact supports breastfeeding, bonding and better health outcomes

Research during the past 30 years has found many benefits of skin-to-skin contact between mothers and newborns immediately after birth, particularly with aiding breastfeeding. However, in some hospitals, skin-to-skin contact following cesarean birth is not implemented, due to practices around the surgery. A recent Quality Improvement (QI) project demonstrated that women's birth experiences were improved by implementing skin-to-skin contact after cesarean surgery.

12 Nov 2014

New research shows hospital workers wash hands less often as workday progresses

Hospital workers who deal directly with patients wash their hands less frequently as their workday progresses, probably because the demands of the job deplete the mental reserves they need to follow rules, according to new research published by the American Psychological Association.

11 Nov 2014

New drug combination shows promise as effective, safe treatment for rheumatoid arthritis

A new drug combination for rheumatoid arthritis treats the disease just as well as other intensive treatment strategies but with less medication and fewer side effects at a significantly lower cost. Doctoral researcher Diederik De Cock (KU Leuven) describes the strategy in a new study published in Annals of Rheumatic Diseases.

11 Nov 2014

National Psoriasis Foundation to hold free psoriatic arthritis program in Dallas-Fort Worth area

If you're one of the roughly 48,000 Dallas-Fort Worth area residents struggling with pain from psoriatic arthritis (PsA)—an inflammatory autoimmune disease that causes pain, swelling and stiffness of the joints and tendons—learn to control your condition with Be Joint Smart, a free psoriatic arthritis program presented by the National Psoriasis Foundation, at the Dallas Marriott Las Colinas on December 6.

10 Nov 2014

Researchers develop standardized, team-based approach to reduce alarm fatigue in hospitals

The sound of monitor alarms in hospitals can save patients' lives, but the frequency with which the monitors go off can also lead to "alarm fatigue," in which caregivers become desensitized to the ubiquitous beeping.

10 Nov 2014

Olaparib shows promise for advanced cancers associated with BRCA1 and BRCA2 mutations

Olaparib, an experimental twice-daily oral cancer drug, produces an overall tumor response rate of 26 percent in several advanced cancers associated with BRCA1 and BRCA2 mutations, according to new research co-led by the Abramson Cancer Center of the University of Pennsylvania.

7 Nov 2014

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy.

5 Nov 2014

Researchers develop new test to identify drugs that could work against Lyme disease

Researchers from the Johns Hopkins Bloomberg School of Public Health have developed a test they say will allow them to test thousands of FDA-approved drugs to see if they will work against the bacteria that causes tick-borne Lyme disease.

4 Nov 2014

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

AstraZeneca and Pharmacyclics, Inc. today announced that they have entered into a clinical trial collaboration to evaluate a novel combination therapy targeting solid tumors.

4 Nov 2014

MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection

Merck Sharp & Dohme Ltd. MSD (known as Merck & Co., Inc. in the United States and Canada), today announced the presentation of results from a Phase 2b clinical trial evaluating the safety and efficacy of once daily oral doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), plus tenofovir/emtricitabine (TDF/FTC) compared to efavirenz plus TDF/FTC in previously untreated patients with HIV-1 infection.

4 Nov 2014

$Adults with eczema at greater risk of accidental bone fractures, other injuries$

Adults with eczema at greater risk of accidental bone fractures, other injuries

Intense itching and dry, irritable skin aren't the only problems adults with eczema face. They are at greater risk of accidental bone fractures and other injuries, a new Northwestern Medicine® study has found.

31 Oct 2014

Pre-treatment pain intensity predicts survival of patients with head and neck cancer

Pre-treatment pain intensity is an independent survival predictor for patients with head and neck cancer, according to new research published in The Journal of Pain, the peer-reviewed publication of the American Pain Society.

28 Oct 2014

Pulmocide uses INTEGRA's VIAFLO Assist pipetting assistant to improve screening of novel compounds

INTEGRA reports on how respiratory drug discovery and development specialists - Pulmocide Ltd. (London, UK) are using a VIAFLO Assist pipetting assistant to enhance the productivity and reproducibility of their screening of novel compounds in a range of biological assays.

From INTEGRA Biosciences 28 Oct 2014

Sleep problems very common among young children receiving treatment for psychiatric disorders

John Boekamp, Ph.D., clinical director of the Pediatric Partial Hospital Program at Bradley Hospital recently led a study that found sleep difficulties - particularly problems with falling asleep - were very common among toddlers and preschool-aged children who were receiving clinical treatment for a wide range of psychiatric disorders.

27 Oct 2014

FDA accepts Eisai's sNDA for perampanel drug for treatment of PGTC seizures

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted for review the company's Supplemental New Drug Application (sNDA) for its in-house-discovered AMPA receptor antagonist perampanel for the treatment of primary generalized tonic-clonic (PGTC) seizures.

20 Oct 2014

Boston Scientific starts PLATINUM Diversity trial to evaluate Promus PREMIER Stent System

As part of its commitment to innovation and improving patient outcomes, Boston Scientific Corporation has initiated the PLATINUM Diversity trial to evaluate the clinical performance of the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System in underserved patient populations, including women and people of color.

20 Oct 2014

Fatigue News and Research

Skin-to-skin contact supports breastfeeding, bonding and better health outcomes

New research shows hospital workers wash hands less often as workday progresses

New drug combination shows promise as effective, safe treatment for rheumatoid arthritis

National Psoriasis Foundation to hold free psoriatic arthritis program in Dallas-Fort Worth area

Researchers develop standardized, team-based approach to reduce alarm fatigue in hospitals

Olaparib shows promise for advanced cancers associated with BRCA1 and BRCA2 mutations

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Researchers develop new test to identify drugs that could work against Lyme disease

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection

Adults with eczema at greater risk of accidental bone fractures, other injuries

Pre-treatment pain intensity predicts survival of patients with head and neck cancer

Pulmocide uses INTEGRA's VIAFLO Assist pipetting assistant to improve screening of novel compounds

Sleep problems very common among young children receiving treatment for psychiatric disorders

FDA accepts Eisai's sNDA for perampanel drug for treatment of PGTC seizures

Boston Scientific starts PLATINUM Diversity trial to evaluate Promus PREMIER Stent System

Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

The Female Athlete Triad: A medical condition in active girls and women

Myths, misconceptions about seasonal flu and flu vaccine

Reducing heart failure deaths: an interview with Dimitrios Georgiopoulos, UK Medical Director, Novartis

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News